Cell metabolismNov 20, 2025

How activating GLP-1 receptors may counter aging across the body through multiple biological systems

Longevity & Aging Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 27, 2026

Abstract

Essence

GLP-1 receptor agonist treatment counteracted many age-related molecular changes and improved selected physical functions in aging male mice.

Evidence

This was a preclinical mouse study with deep multi-omic profiling and functional assessment after GLP-1RA treatment from 11 months for 30 weeks or from 18 months for 13 weeks, including hypothalamic GLP-1R dependence and comparison with mTOR inhibition.

Caveat

The results are limited to male mice and molecular or selected functional endpoints, so they do not prove body-wide anti-aging benefit in humans.

Simplified

Identifying practical ways to counteract aging and associated degenerative disorders is urgently needed. We performed deep molecular profiling and functional assessments in aging male mice to show that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment broadly counteracts age-related changes. In mice treated with a GLP-1RA from 11 months for 30 weeks, we observed strong body-wide multi-omic age-counteracting effects and improved selected physical functions. Importantly, the effects were specific to aged mice, not young adults, and were attained with a relatively low dose that minimally affected food intake or body weight. With GLP-1RA treatment beginning at 18 months for 13 weeks, the molecular age-counteracting effects were even stronger and largely dependent on hypothalamic GLP-1R, pointing to a brain-body axis of aging modulation. Comparison with mammalian target of rapamycin (mTOR) inhibition, a proven anti-aging strategy, revealed strong multi-omic similarities. Our findings have broad implications for the mechanisms behind GLP-1RAs' pleiotropic benefits, guiding clinical trials, and informing development of anti-aging-based therapeutics.